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Abstract:
Severe asthma is a relatively uncommon condition in children but one 
which causes morbidity, occasionally mortality and is a challenging 
condition to manage.  There are several definitions of severe asthma 
which have a common theme of poor control despite high dose inhaled 
corticosteroid treatment.  Severe asthma can be considered as difficult 
to treat or therapy resistant, or both.  Depending on the definition 
chosen, the prevalence of severe childhood asthma may be up to 5% 
within populations with asthma.  Collectively there is some evidence that 
the treatments used in severe asthma are beneficial, but a solid 
evidence-base is lacking for many treatments and some treatments have 
recognised side-effects.  Evidence supporting the use of maintenance 
oral prednisolone and intramuscular triamcinolone is weak.  Response to 
corticosteroids is heterogeneous and recognising phenotypes or 
endotypes may identify those most likely to gain maximal benefit from 
treatment.  For children aged 6-11 years the anti-IgE biologic 
omalizumab is effective an anti-IL-5 agent (mepolizumab) has recently 
been licenced in Europe (but not the US). Biologics which are licenced for 
>11 year olds include omalizumab, mepolizumab, benralizumab, 
reslizumab and dupilumab.  There is plenty that the clinician can offer to 
the child and adolescent with severe asthma in 2019, including non-
therapeutic and therapeutic interventions.  To manage severe asthma, 
practitioners from broad specialties must establish and maintain a close 
therapeutic relationship with patients.  Looking beyond 2019, more 
treatment options will emerge for severe childhood asthma, and clinical 
teams will need to continue weighing up benefits and harms.  
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ABSTRACT
Severe asthma is a relatively uncommon condition in children but one which causes morbidity, 
occasionally mortality and is a challenging condition to manage.  There are several definitions of 
severe asthma which have a common theme of poor control despite high dose inhaled corticosteroid 
treatment.  Severe asthma can be considered as difficult to treat or therapy resistant, or both.  
Depending on the definition chosen, the prevalence of severe childhood asthma may be up to 5% 
within populations with asthma.  Collectively there is some evidence that the treatments used in 
severe asthma are beneficial, but a solid evidence-base is lacking for many treatments and some 
treatments have recognised side-effects.  Evidence supporting the use of maintenance oral 
prednisolone and intramuscular t iamcinolone is weak.  Response to corticosteroids is 
heterogeneous and recognising phenotypes or endotypes may identify those most likely to gain 
maximal benefit from treatment.  For children aged 6-11 years the anti-IgE biologic omalizumab is 
effective an anti-IL-5 agent (mepolizumab) has recently been licenced in Europe (but not the US). 
Biologics which are licenced for >11 year olds include omalizumab, mepolizumab, benralizumab, 
reslizumab and dupilumab.  There is plenty that the clinician can offer to the child and adolescent 
with severe asthma in 2019, including non-therapeutic and therapeutic interventions.  To manage 
severe asthma, practitioners from broad specialties must establish and maintain a close therapeutic 
relationship with patients.  Looking beyond 2019, more treatment options will emerge for severe 
childhood asthma, and clinical teams will need to continue weighing up benefits and harms.  
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INTRODUCTION
Asthma is a common condition which is managed in many countries and in millions of children and 
adolescents around the globe according to regional, national and international guidelines1,2.  The 
purpose of management is to increase preventative treatment in response to increasing symptoms 
and reduce treatment when symptoms are controlled.  The reactive nature to childhood asthma 
management is associated with less-than-ideal control of symptoms3 and asthma exacerbations 
remain common, for example in the UK a child is admitted to hospital due to an asthma 
exacerbation every 20 minutes4.   
In a proportion of children and adolescents, troublesome daily asthma symptoms and/or frequent 
asthma attacks can occur, and in this context asthma is said to be “severe”.  Severe childhood 
asthma is associated with morbidity, mortality and healthcare expense, and is a particularly 
challenging situation for the child and young person, their family, their healthcare team and the 
wider healthcare system.  The diagnosis and management of asthma remain predominantly 
subjective and this is especially true for severe asthma.  Current guidelines1,2 are more appropriate 
for mild asthma and limited by the fact that, to date, clinical trials have not adequately addressed 
the treatment options for severe asthma in children. 
The uncertainties surrounding the diagnosis and management of severe childhood asthma have 
been reviewed on a regular basis5–12.  The aims of this review are (i) to describe the different 
definitions of severe asthma and to identify which components are common to all and which are not 
consistently included (ii) to describe the epidemiology of severe asthma and (iii), knowing that the 
benefits and harm from commonly used inhaler medications and oral montelukast are described 
elsewhere1,2,13, our final aim was to  review the evidence of benefit and harm from the systemic 
medications currently used in severe asthma. 
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Definitions of severe asthma
There is no uniformly-accepted definition of asthma, so not unexpectedly there are several 
definitions of severe asthma1,2,6,14–17 and these are described in table one.   In addition to severe 
asthma there are other terms such as “brittle” and “refractory” asthma which are not defined but 
may be used interchangeably with severe asthma.  The two themes common to all the definitions of 
severe asthma identified are poor symptom control and high dose treatment (usually inhaled 
corticosteroid, ICS ≥400 micrograms budesonide or equivalent for children aged under 12 years and 
≥1000 micrograms in older children2).  Asthma attacks are included in some but not all definitions of 
severe asthma.  
Severe asthma can be broken down into two subcategories6.  A substantial proportion of individuals 
with severe asthma has symptoms which are due to modifiable factors which include poor or non-
adherence and/or poor inhaler technique, and these children and adolescents can be considered as 
having “difficult to treat asthma”.  The second subcategory of severe asthma is termed “therapy 
resistant asthma” and describes children and adolescents whose symptoms are resistant (or in some 
cases partially resistant) to standard treatments such as inhaled and oral corticosteroids, long acting 
beta agonists and leukotriene modifiers.  There is a pressing need to categorise individuals correctly 
since management approaches to these two subcategories of severe asthma are divergent.  The 
management of difficult to treat asthma is rooted in education and psychology, whereas the 
management of therapy resistant asthma is “non-standard” pharmacological therapies.  To further 
complicate matters, many individuals with therapy resistant asthma also have characteristics of 
difficult to treat asthma. Ultimately the diagnosis of severe asthma, and its difficult to treat asthma 
and therapy resistant subcategories, is easiest made with the benefit of hindsight, but clinicians do 
not have this luxury during initial encounters with a patient whose asthma may be severe.
Faced with a child or adolescent with a possible severe asthma diagnosis, clinicians need to consider 
possibilities which are more fully described elsewhere 1,6–8,18,19 and summarised here: 
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1. Is this asthma? Conditions such as dysfunctional breathing, vocal cord dysfunction are 
increasingly recognised in children aged five years and above, and are reviewed elsewhere 
20,21.  Pertussis22 and habitual cough23 are commonly treated with escalating asthma 
medications in school aged children.  The “traditional” differential for asthma includes cystic 
fibrosis, primary ciliary dyskinesia, foreign body, immune deficiency, congenital airway 
pathologies such as tracheomalacia1, but these are predominantly considerations for the 
under five year olds.  Confirmation of the diagnosis includes typical symptoms, fixed airflow 
limitation and a response of symptoms and physiology to a defined period of supervised 
treatment1,2. 
2.  Is this difficult to treat asthma?  Inhaler technique is generally poor in children and 
adolescents24 and this can usually be easily identified and readily resolved.  Addressing poor 
or non-adherence is less straight forward than addressing poor inhaler technique.  
Treatment non-adherence in asthma is reviewed elsewhere25.   Briefly, adherence to 
medication is a complex behaviour and non-adherence can be due to a number of factors 
including denial of the diagnosis, fear of harm from the medication, lack of understanding 
about the importance of taking the medication, not considering asthma a priority and having 
a secondary gain from the presence of symptoms, e.g. school avoidance.  Adherence can be 
categorised as intentional or unintentional.  Non-adherence can include situations where 
medication is never taken, medication is discontinued (by the patient) and medication is 
taken but not as frequently as prescribed.  Socioeconomic factors often contribute to poor 
adherence, and these include limited access to health care professionals and treatment.  
“Family factors” may also contribute to poor adherence, for example if the family has little 
or no organisation in the day-to-day running of the household then attention to taking 
treatment is likely to be poor, and where there is scepticism or mistrust of healthcare 
professionals treatment adherence can be expected to be poor.
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3. Are there treatable co-morbidities?  Anxiety and allergic conditions such as rhinitis and 
eczema should be identified and managed since they can accompany and contribute 
towards poor quality of life for children and adolescents with severe asthma.  Other 
conditions such as obesity, obstructive sleep apnoea and gastro-oesophageal reflux disease 
(GORD) may accompany severe asthma but interventions aimed at reducing obesity or 
treating GORD have not been shown to improve asthma symptoms19.
4. Are there avoidable adverse environmental exposures contributing to symptoms? In the 
absence of a clear history of an exposure leading to symptoms, for example contact with a 
cat or eating a peanut, this can be difficult to ascertain.  A home visit may be revealing.  
Exposure to second hand smoke or visible mould in the bedroom may be contributory.  
5. Is this therapy resistant asthma? Consider corticosteroid resistance by non-response to a 
dose of triamcinolone or a burst of prednisone. 
6.  Might a bronchoscopy and biopsy help? This may be helpful in excluding a large airway 
pathology which is masquerading as asthma.  In some centres the role of airway biopsy in 
stratifying asthma treatment is being assessed19. 
Epidemiology of severe asthma
Studying the epidemiology of severe asthma is difficult due to its low prevalence, the use of different 
definitions and the presence of only a few whole population studies.  Key questions include what is 
the average age of a child with severe asthma? is there a difference in prevalence between males 
and females? And what is the prevalence of severe asthma? 
Severe asthma occurs across the paediatric age range, and in children aged less than five years is 
poorly understood.  Anecdotally, in the under five years age group severe exacerbations occur with 
intercurrent upper respiratory tract infection against a back ground of relatively well-controlled 
symptoms, and this pattern is generally considered as distinct from severe asthma in older children.  
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Cases series of treatment with intramuscular triamcinolone for severe asthma26–30 indicate that 
severe asthma is more common in the 12-15 year age group but there is no consistent male or 
female majority (table 2).  The 188 children with severe asthma in the Severe Asthma Research 
Program (SARP) III31 and the 99 children with severe asthma an initiative aimed at characterising 
severe asthma (U-BIOPRED)32 were typically 11-12 years old and 55-60% were male.  The complexity 
of the relationship between gender, age and asthma severity is demonstrated in an observational 
study of asthma which concluded that the proportion of asthmatic patients recruited who had 
severe asthma increased in boys as they became older (34% in the youngest and 59% in the oldest 
age group) but the proportion did not increase significantly as girls became older (33% and 52% 
respectively)33.  This study also found that among white children, 54% of 9-11 year olds with severe 
asthma were female increasing to 80% in the 15-17 year age group but this was not seen among 
black females33.  
Where it is described, severe asthma prevalence diminishes as more stringent definitions are 
applied, e.g asthma mortality versus prescribing of high dose inhaled corticosteroids (ICS) versus 
self-reported severity.  Routinely collected data indicate that the incidence of mortality from asthma 
in children is between 0 and 2 per million children per annum in European countries (figure one)34, 
but mortality may be as high as 7 per million per annum in some non-European countries35.  The 
international differences in mortality is illustrated when comparing data from the UK36 (3 per million 
per annum) and Finland37 (0.2 per million per annum), and this difference may reflect differences 
between healthcare systems.  Birth cohort studies from Northern Europe estimate the prevalence of 
severe asthma is between 2 and 5 per thousand children or 2-5% of all children with asthma38,39.  
Consistent with these findings, studies using primary care prescribing data in England40 and 
Scotland41 also found that approximately 5% of children with asthma were prescribed very high dose 
ICS.  A European study also found that 5% of parents of children with asthma scored their child’s 
asthma as being severe3.  When using self-reported questionnaires, the prevalence of severe asthma 
symptoms (defined as ≥4 attacks of wheeze or ≥1 night per week sleep disturbance from wheeze or 
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wheeze affecting speech in the past 12 months) in adolescents ranges between 38 and 51% with the 
higher proportions being seen in low and middle income countries35.
Systemic medications used for severe asthma
In the absence of high quality evidence, guidelines cannot say which medications should be 
considered beyond the “top step” of the stairway of escalating treatment. The mainstay of asthma 
treatment is inhaled corticosteroids and, when required, the addition of inhaled long acting beta 
agonists, leukotriene receptor antagonists and theophylline1,2. When these treatments are 
considered to be inadequate, treatment options mentioned in guidelines include long term oral 
corticosteroids, intramuscular omalizumab (an anti-IgE antibody) and anti-reflux treatments.  
Historically, “beyond the guidelines” treatments have followed an “ECG course” (figure one) where 
there is a spark of interest (P-wave) followed by a wave of enthusiasm shortly followed by a rapid loss 
of enthusiasm (QRS complex).  Finally, there is a small amount of use in some contexts and regions (T 
wave) before practice ceases completely.  Historically, experimental “beyond the guidelines” 
therapies which have been through the “ECG course” include oral macrolides, cyclosporin, cytotoxic 
drugs such as methotrexate and azathioprine, gold salts, intravenous infusions of Immunoglobulin, 
subcutaneous beta-agonist treatment and, in those sensitised to fungi, oral antifungal therapy with 
itraconazole or voriconazole8. This process of “trial and error” is now less commonplace and today’s 
novel therapies, for example biologics, emerge from a more robust scientific foundation.
Systemic corticosteroids
There is a high level of evidence that short bursts of oral corticosteroid (OCS) treatment (e.g. for 
three or five days) are effective in reducing the severity and duration of an asthma exacerbation in 
children42.  This experience has been extrapolated to the different setting of chronic poorly 
controlled asthma symptoms, and some children and adolescents can receive maintenance daily or 
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alternate daily OCS treatment for periods in excess of one month. There is absence of evidence for 
efficacy of “maintenance” OCS despite this treatment being in asthma guidelines1,2.  Maintenance 
OCS treatment should ideally be under the supervision of a respiratory expert who can minimise the 
risk for wrong diagnosis and likely distinguish difficult to treat asthma from therapy resistant 
asthma, but the use of maintenance OCS in severe childhood asthma remains an evidence-free area.  
Most experienced paediatric pulmonologists can readily recall a (typically adolescent) patient who 
required maintenance OCS prescriptions for a period of months to gain symptom control and then 
were successfully weaned off their OCS.  
What is clear is that oral corticosteroid treatment is known to have adverse effects in children when 
used in short bursts (vomiting, behaviour change and sleep disturbance)43 and also for periods in 
excess of 14 days (weight gain, growth retardation, cushingoid features and susceptibility to 
infection)44.  The potential for harm from maintenance OCS to be greater than benefit is highlighted 
in BTS/SIGN guideline1 which states for adults (i.e. those aged >12 years): “add on low dose oral 
corticosteroids (7.5mg prednisolone daily) may be effective for some adults with severe asthma 
(Evidence D[i.e. based on very poor quality evidence]) but are associated with substantial side 
effects (Evidence B[i.e. based on good quality evidence]).”
Intramuscular Triamcinolone
Intramuscular treatment with triamcinolone may have a role in identifying steroid-responsive 
asthma, and may also provide treatment in severe asthma where adherence to inhaled and/or oral 
corticosteroids is in question (approximately 50% of adults with severe asthma are non-adherent 
with oral corticosteroid treatment45). Evidence supporting the use of this systemic treatment in 
children is limited to case series where different doses of triamcinolone are used26–30, see table two.  
The third phase of the US Severe Asthma Research Program (SARP III) included the largest case 
series where triamcinolone was used to treat asthma symptoms.   The aim of the study was to 
identify determinants of steroid responsiveness in 188 children and 526 adults who had extensive 
Page 10 of 54
John Wiley & Sons, Inc.
Pediatric Pulmonology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
10
physiological assessments before and three weeks after a single dose of triamcinolone.  
Triamcinolone treatment was associated with significant falls in exhaled nitric oxide and blood 
eosinophil count.  Among 111 children with severe asthma there was an improvement in symptoms 
and a non-significant trend for improved pre bronchodilator FEV1.  The apparent lack of response to 
triamcinolone in children with non-severe asthma is likely to be explained by a small sample size 
with few symptoms and good initial FEV1, and not necessarily by a lack of steroid-responsiveness.  A 
second in a case series of 79 children27, also sought to describe symptom and physiological 
outcomes four weeks after a single dose of intramuscular triamcinolone, which was given as part of 
a well-described pathway of care.  Children had improved symptom score (as evidenced by Asthma 
Control Test) and spirometry, and the differences were more clearly seen in children categorised as 
white compared to black.  Sputum eosinophilia, exhaled nitric oxide and intensive care unit 
admissions were all reduced after treatment but only among white children. 
A third prospectively-recruited case series28 identified children with an “unacceptably high level” of 
symptoms and admissions despite regular short bursts or continuous oral corticosteroid treatment 
and where adherence was considered adequate (including checking on the number of inhalers 
collected).  Individuals were given either one treatment of triamcinolone or repeated treatments at 
one month intervals. The number of exacerbations and hospital admissions during the treatment 
and post treatment phases fell relative to pre-treatment among those with repeated triamcinolone 
treatments.  Among those given a single treatment with triamcinolone, exacerbations but not 
hospital admissions were reduced.  In all participants, the number of day’s treatment with oral 
corticosteroid fell close to zero. Side effects were minimal and limited to the injection site. The 
authors conclude “Whether its [i.e. Triamcinolone] efficacy is due to improved compliance, or an 
improved anti-inflammatory profile compared with oral steroids, remains unclear”.   Two 
retrospective case series published as separate abstracts29,30 and which are summarised in table 2 
report beneficial and adverse treatment outcomes in a total of 12 children.   
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Collectively these data should be considered with caution since their “open label” design, absence of 
placebo and (in two cases29,30) their retrospective design mean that it is not reasonable to infer 
beyond doubt that any benefits arose from triamcinolone treatment.  The worrying side effects 
reported in one series29 should be considered, albeit other case series did not mention side 
effects27,30 and the fourth study mentioned only minor local effects28.  As with most asthma 
treatments, response to triamcinolone is not homogeneous and results from one study indicate that 
a response may be more clearly seen in white children compared to black27.  When adherence to 
maintenance oral corticosteroid treatment is uncertain and the child or young person is experiencing 
severe or life-threatening asthma exacerbations, then it would be reasonable to start a short trial of 
triamcinolone treatments to demonstrate whether symptoms are steroid responsive.  If there is no 
response to at least two months treatment and/or side effects develop then treatment might be 
discontinued.  If there is a response (in asthma control and number of exacerbations) then strategies 
to improve inhaled or oral corticosteroid adherence should be explored.
Omalizumab
The anti-IgE antibody omalizumab has been used for the treatment of severe asthma in children 
aged 6-11 years since 2009, and in older children and adults since 2003.  At least ten randomised 
controlled trials in children have explored the efficacy of omalizumab in a range of settings including 
“persistent asthma”, “severe asthma” and “moderate-to-severe atopic asthma” and the consensus is 
that treatment is safe and effective in reducing asthma exacerbations (especially in the September 
peak in asthma exacerbations), reducing ICS dose and reducing symptoms46.  When first introduced, 
there were concerns about anaphylaxis and increased risk for malignancies (mostly extrapolated 
from anxieties about infliximab, an antibody specific for tumour necrosis factor), but a recent review 
noted that risk of anaphylaxis was approximately 0.2% per treatment and there was no excess of 
malignancies46.  Omalizumab is not suitable for all patients, the largest trial47 included in a recent 
review46 found that the majority (59%) of potential participants were ineligible.  The monthly 
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subcutaneous injection is uncomfortable, requires administration in a healthcare setting with 
nursing observations and is expensive.  What remains to be clarified is whether it is superior to high 
dose ICS, and how and when treatment should be discontinued. 
Mepolizumab
The anti-interleukin-5 molecule mepolizumab was licenced in Europe for use in children aged 6-11 in 
August 2018 and has been licenced for use in older children in the US and Europe since 2015.  
Experience with this “mab” in adults was initially mixed, with some studies finding improved asthma 
outcomes but most studies reported severe headaches48; a definitive trial found that mepolizumab 
was effective in reducing asthma exacerbations and a licence was granted in 201548.
The license in Europe for children is based only on safety data from a single study of 36 6-11 year 
olds49. Inclusion criteria included: having an asthma diagnosis for more than 12 months; at least two 
exacerbations in the year prior to recruitment; receiving ≥400 micrograms budesonide daily (or 
equivalent); receiving an additional controller medication for more than three months; an FEV1/FVC 
ratio of <0.8 and blood eosinophilia (>0.15x109/l on r cruitment or >0.3 x109/l in the year prior to 
recruitment).  In keeping with the adult experience, headaches were a common side effect.  Clinical 
improvements were not sought in this phase II trial so the efficacy of this treatment remains 
uncertain in children.  Given the challenge in recruiting children fulfilling these inclusion criteria, it is 
likely that a randomised clinical trial will not be carried out.  
Data from studies in adults (but including participants as young as 12 years) have demonstrated the 
efficacy of mepolizumab for reducing risk of asthma exacerbations.  The DREAM study enrolled 621 
participants (159 received a placebo), who had at least two asthma attacks in the previous year, 
“airway variability” (i.e. either peak flow variability, bronchial hyperresponsiveness or 
bronchodilator response) and eosinophilia (i.e. elevated exhaled nitric oxide or blood eosinophilia).  
Treatment with one of three doses of mepolizumab was associated with between a 39-52% 
reduction in the rate of exacerbations, but there was no improvement in asthma control between 
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the placebo and treatment groups50.  The MENSA study recruited 576 participants aged 12-82 years 
of whom 191 received placebo treatment and who had very similar characteristics to the DREAM 
study (namely two recent asthma attacks, airway variability and eosinophilia).  There was 
approximately a 50% reduction in asthma exacerbations for those treated with mepolizumab 
compared to placebo and also a small improvement in asthma symptoms (but which was not greater 
than the minimal clinically important change)51. 
For patients aged twelve years and older, there are two other anti IL5 pathway specific therapies 
licensed (benralizumab and reslizumab).  A recent review of the literature suggests that whilst all 
three anti IL-5 pathway specific therapies are more effective than placebo in reducing exacerbations 
and improving symptom control, mepolizumab has the greatest benefit52. 
Dupilumab 
Dupilumab is an IL-4 and IL-13 antibody which is licensed in the US and European Union for the 
management of severe asthma in individuals who are aged 12 years and older.  The LIBERTY 
ASTHMA QUEST study 53 recruited 1902 participants aged at least 12 years who were randomised to 
either placebo or one of two subcutaneous doses of dupilumab given at two weekly intervals over a 
12 month period.  Inclusion criteria included: prescribed medium-high dose ICS treatment; 
prescribed an additional controller; FEV1 <80% (or ≤90% for 12-17 year olds); bronchodilator 
reversibility (>12% or 200mls); poor symptom control (Asthma Control Questionnaire score ≥1.5); 
and an asthma attack requiring systemic glucocorticosteroid treatment in the last year.  The primary 
outcome was exacerbation rate and, as seen for other “-mabs” the rate of exacerbations was 
reduced by approximately half (47.7%) in those receiving active treatment compared to placebo.  
The dupilumab group had improved symptom scores after two week’s treatment and thereafter 
throughout the study, also they had a mean increase of 140mls in FEV1 compared to the placebo 
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group.  Eosinophilia (i.e. >300 eosinophils per cubic millimetre) occurred in 4% of participants who 
received dupliumab and 0.6% who received placebo, the clinical significance of this is uncertain.
Gastro-oesophageal reflux treatment
Gastro-oesophageal reflux disease (GORD) is commonly present in adults and children with asthma.  
In the adult literature there was evidence of benefit (in terms of improved lung function) when 
patients with night time respiratory symptoms and GORD were treated with esomeprazole54 but this 
same medication was not associated with improved lung function or reduced symptoms in the 
absence of GORD symptoms54,55.  Despite the relationship not being thought to be causal1, a trial of 
GORD treatment is sometimes used in children with severe asthma.  An evidence base for this 
practice is lacking.  One randomised controlled trial explored the benefit of a proton pump inhibitor 
(Lansoprazole) in poorly controlled (not severe) asthma in 306 children aged 6-17 years56. Eligibility 
criteria included receiving a dose of ICS >175 micrograms/day fluticasone (or equivalent), evidence 
of airway reversibility or hyperresponsiveness, need for short acting beta agonist treatment more 
than two days a week and two asthma exacerbations in the past year.  Children and adolescents 
with overt GORD symptoms were excluded, but just over 40% of participants tested had evidence of 
GORD.  After 24 weeks there were no differences in asthma outcomes between those who received 
lansoprasole compared to placebo.  Unexpectedly the active medication was associated with 
increased risk for respiratory infection.  
Conclusions
Severe asthma in children will continue to be a clinical challenge and brings a risk of morbidity and 
mortality due to the disease itself and also potentially from the treatment offered.  This review has 
highlighted ongoing areas of uncertainty in the definition, the epidemiology and the medical 
treatment of severe asthma (table three).  The future is likely to continue to bring more treatment 
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options for severe asthma which may offer benefit but also may prove to be a “flat line” after the 
ECG course.  For example the roles of long acting muscarinic agonists, macrolide antibiotics and 
bronchial thermoplasty in children are unknown at present, but will likely be explored in future.   
There is a sound evidence base that electronic logging of inhaled corticosteroid treatment leads to 
improved asthma outcomes, and such meters may become more commonly used in clinical 
practice57,58.  Directly observed inhaler treatment using video conference technology may also be 
useful in some situations59.  Among other non-medicinal interventions there are new “uncertainties” 
such as temperature-controlled laminar airflow60 and old “uncertainties” such as dust mite 
impermeable bedding61.  Severe asthma will always test clinical teams and sometimes call for 
difficult decisions to be made.  Key to management are involving the asthma team, speaking to other 
professionals involved (e.g. teachers) and personalising care.
Research needs
These are some areas where further research might advance the care for children and adolescents 
with severe asthma.
 What is the prevalence and incidence of severe asthma in children (using different 
definitions)? 
 What objective tests are most effective in distinguishing between difficult to treat and 
therapy resistant asthma (e.g. spirometry, plasma prednisolone concentration, inhaler 
logging devices, directly observed therapy)?
 How and when should treatment with maintenance oral corticosteroids and intramuscular 
triamcinolone or biologics begin and when might they be stopped?
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FIGURE LEGENDS
Figure one. Schematic “ECG” summarising the ups and downs of enthusiasm for many novel 
treatments which have been used for severe asthma in the past, but which are no longer used8.  In 
this metaphor, treatment is first proposed as being potentially of use (P wave), then followed by a 
surge of enthusiasm (upwards limb of the QRS complex) followed by reality (downwards limb of the 
QRS complex), then a short burst of use by a few enthusiast (T wave) after which the medication is 
never used.
Figure two. The incidence of asthma morbidity in 21 countries in the World health Organisation 
European Region averaged between 2006 and 2015.  Only countries where data were available in 
each year and where at least one year had an incidence which was not zero.  Data were available 
between 2006-2015 and the incidence was zero throughout from the following countries: Cyprus, 
Estonia, Israel, Lithuania and Malta.
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Table one.  A summary of the definitions of severe asthma in children and young people
MentionSource of the definition Exact wording
High dose 
therapy
Poor 
control
Exacerbations
Global Initiative for Asthma 20172 Asthma that requires step 4 or 5 treatment, e.g. high dose ICS/LABA, to prevent it 
becoming uncontrolled, or asthma that remains uncontrolled despite this 
treatments
Yes Yes No
British Thoracic Society and Scottish 
Intercollegiate Guidelines Network 
Guideline for the Treatment of Asthma1
2016
A prior diagnosis of asthma exists, and asthma-like symptoms and asthma attacks 
persist, despite prescription of high-dose asthma therapy
Yes Yes Yes
European Respiratory Society/American 
Thoracic Society guidelines on definition, 
evaluation and treatment of severe 
asthma3
2014
Asthma which requires treatment with high dose inhaled corticosteroids (ICS) plus 
a second controller (and/or systemic corticosteroids) to prevent it from becoming 
‘uncontrolled’ or which remains ‘uncontrolled’ despite this therapy
Yes (ICS) Yes No
Problematic 
Severe Asthma
School-age children who, despite prescribed therapy of ≥800 mg/day inhaled 
corticosteroid (budesonide or equivalent), have undergone trials of at least two of 
three controllers (long-acting b-agonist, leukotriene receptor antagonist and oral 
theophylline) and still have symptoms
Difficult-to-treat 
asthma
When poor control is due to one or more of the following: associated diagnoses 
(comorbid conditions), poor adherence to treatment regimens, or adverse 
psychological and environmental factors
Problematic Severe 
Asthma in Childhood 
Initiative group4
2010
Severe therapy-
resistant 
asthma
When factors that make the child difficult to treat cannot be identified
Yes Yes No
World Health Organisation5 
2010
'Uncontrolled asthma which can result in risk of frequent severe exacerbations (or 
death) and/or adverse reactions to medications and/or chronic morbidity
No Yes 
(morbidity)
Yes
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American Thoracic Society and Severe 
Asthma Research Programme 20006
Refractory asthma (after excluding other conditions, obvious environmental 
triggers and non-adherence) requires ≥1 major and ≥2 minor criteria
Major criteria
1. Continuous/near continuous oral corticosteroid treatment
2. High dose inhaled corticosteroids
Minor criteria
1. Daily treatment with additional preventer, e.g. long acting beta agonist
2. Daily/near daily short acting beta agonist treatment
3. Persistent airway obstruction, e.g. FEV1 <80%
4. At least one urgent care visit per year
5. A least three “bursts” of oral corticosteroid treatment per year
6. Prompt deterioration after reduction in maintenance oral or inhaled 
corticosteroid treatment
7. Past history of a near fata asthma episode
Yes Yes (minor 
criteria 2)
Yes
European Respiratory Society Task Force 
on Difficult/therapy-resistant asthma, 
19997
Difficult/therapy-resistant asthma is that which is poorly controlled in terms of 
chronic symptoms, episodic exacerbations, persistent and variable airways 
obstruction and a continued requirement for short-acting b2-agonists despite
delivery of a reasonable dose of inhaled corticosteroids Patients may require 
courses of oral corticosteroids or a regular dose of oral corticosteroids to maintain 
reasonable control of the disease. Rarely, control of asthma may be totally 
uninfluenced by corticosteroid therapy.
Yes Yes Yes
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Table two.  Details of case reports where intramuscular triamcinolone was used as part of asthma management.
Study Number of participants Dose of triamcinolone 
used and interval
Outcome after treatment
Koo et al1 79 cases (age and sex distribution not stated) 40 or 80mg 
(if < or ≥30 kg) one 
dose given
Exhaled nitric oxide, sputum eosinophilia and admissions for 
asthma were reduced in white children
Panikar2 5 cases given one dose (mean 9 years, range 5-13 years, 2 
female)
8 given 2-5 doses (mean 13 years, range 12-15 years, 5 female)
20-100 mg at 4 weekly 
intervals
>1 dose was associated with reduced admissions and 
exacerbations even after ending treatment.  A single dose was 
associated with reduced exacerbations.
Kapur3 7 cases (mean 12, range 8-16 years, 6 female) ≤60 mg (usually 40mg) 
interval between 
doses not stated
No improvement in 2 cases. Self-reported improvement in 3 
cases. Overall improvement in FEV1.  All reported adverse effects. 
Treatment discontinued in two due to adverse effects.
Krupp 4 5 cases (8-15 years, sex distribution not stated) 60-120 mg
interval between 
doses not stated
The collective number of admissions fell to zero
Phipatanakul5 188 children (mean 11.5 years, range 6-17 years, overall 62% 
male)
One dose, 40mg/kg up 
to a maximum of 
40mg
Assessment three weeks after treatment found reduced FeNO 
and blood eosinophils in all participants.  Additionally, among 111 
participants with severe asthma, treatment was associated with 
increased symptom score.  FEV1 did not change after treatment. 
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Table three.  A summary of the evidence for efficacy and side effects of medications included in this review. 1=evidence from systematic review or 
randomised control trials, 2=evidence from open label trial, 3=anecdotal evidence or case series. The minus sign indicates no evidence of efficacy, the plus 
signs indicate the magnitude of efficacy and of side effects
Efficacy? Side effects?
Prednisolone 3+ 1+++
Triamcinolone 3+ 3++
Omalizumab 1+++ 3+
Mepolizumab No data 2++
Lanzoprazole 1- 3+
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Figure one. Schematic “ECG” summarising the ups and downs of enthusiasm for many novel treatments 
which have been used for severe asthma in the past, but which are no longer used8.  In this metaphor, 
treatment is first proposed as being potentially of use (P wave), then followed by a surge of enthusiasm 
(upwards limb of the QRS complex) followed by reality (downwards limb of the QRS complex), then a short 
burst of use by a few enthusiast (T wave) after which the medication is never used. 
254x190mm (96 x 96 DPI) 
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Figure two. The incidence of asthma morbidity in 21 countries in the World health Organisation European 
Region averaged between 2006 and 2015.  Only countries where data were available in each year and 
where at least one year had an incidence which was not zero.  Data were available between 2006-2015 and 
the incidence was zero throughout from the following countries: Cyprus, Estonia, Israel, Lithuania and Malta. 
338x190mm (96 x 96 DPI) 
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Severe asthma in children – a review of definitions, epidemiology and treatment options in 2019
Husam Ahmed, Steve Turner MD
Child Health, University of Aberdeen
Contact details:  Prof Turner, Child Health, Royal Aberdeen Children’s Hospital, Aberdeen, UK, AB25 
2ZG.  Tel +44 1224 438470.  s.w.turner@abdn.ac.uk.
Key words:  Asthma, Biologics, Child, Corticosteroids, Randomised Controlled Trial
Running head: Severe asthma in children and adolescentsyoung people
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ABSTRACT
Severe asthma is a relatively uncommon condition in children and adolescents but one which causes 
morbidity, occasionally mortality and is a challenging condition to manage.  There are several 
definitions of severe asthma which have a common theme of poor control despite high dose inhaled 
corticosteroid treatment, and some definitions also include regular exacerbations.  Severe asthma 
can be considered as difficult to treat or therapy resistant or both.  The prevalence of severe asthma 
within populations of children and adolescents with asthma may be up to 5% depending on the 
definition chosen.  Collectively there is some evidence that the treatments used in severe asthma 
are beneficial, but a solid evidence-base is lacking for many treatments and some treatments have 
recognised side-effects.  Evidence supporting the use of maintenance oral prednisolone and 
intramuscular triamcinolone is weak but there is evidence of adverse effects.  Response to 
corticosteroids is heterogeneous and recognising phenotypes (which may include ethnicity) or 
endotypes (which may include eosinophilia) may identify those most likely to gain maximal ise 
benefit from treatment.  There is a robust evidence base describing the efficacy and side effects for 
the anti-IgE biologic omalizumab.  A second biologic, an anti-IL-5 agent mepolizumab, has recently 
been licenced in Europe (but not the US) for children aged 6-11 years based on safety data but 
without efficacy data. Biologics which are licenced for use in patients over 11 years old include 
omalizumab, mepolizumab, benralizumab, reslizumab and dupilumab.  A randomised controlled trial 
found that proton pump inhibitor treatment does not improve asthma control but may have side 
effects.  There is plenty that the clinician can offer to the child and adolescent with severe asthma in 
2019, including non-therapeutic and therapeutic interventions.  To manage severe asthma, 
practitioners from broad specialties must establish and maintain a close therapeutic relationship 
with patients.  Looking beyond 2019, more treatment options will emerge for severe childhood 
asthma, and clinical teams will need to continue weighing up benefits and harms.  
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INTRODUCTION
Asthma is a common condition which is managed in many countries and in millions of children and 
young peopleadolescents around the globe according to regional, national and international 
guidelines1,2.  The purpose of management is to increase preventative treatment in response to 
increasing symptoms and reduce treatment when symptoms are controlled.  The reactive nature to 
childhood asthma management is associated with less-than-ideal control of symptoms3 and asthma 
exacerbations remain common, for example in the UK a child is admitted to hospital due to an 
asthma exacerbation every 20 minutes4.   
In a proportion of children and young peopleadolescents, troublesome daily asthma symptoms 
and/or frequent asthma attacks can occur, and in this context asthma is said to be “severe”.  Severe 
childhood asthma is associated with morbidity, mortality and healthcare expense, and is a 
particularly challenging situation for the child and young person, their family, their healthcare team 
and the wider healthcare system.  The diagnosis and management of asthma remain predominantly 
subjective and this is especially true for severe asthma.  Current guidelines1,2 are more appropriate 
for mild asthma and limited by the fact that, to date, clinical trials have not adequately addressed 
the treatment options for severe asthma in children. 
The uncertainties surrounding the diagnosis and management of severe childhood asthma have 
been reviewed on a regular basis5–12.  The aims of this review are (i) to describe the different 
definitions of severe asthma and to identify which components are common to all and which are not 
consistently included (ii) to describe the epidemiology of severe asthma and (iii), knowing that the 
benefits and harm from commonly used inhaler medications and oral montelukast are described 
elsewhere1,2,13, our final aim was to  review the evidence of benefit and harm from the systemic 
medications currently used in severe asthma. 
Page 34 of 54
John Wiley & Sons, Inc.
Pediatric Pulmonology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4
Definitions of severe asthma
There is no uniformly-accepted definition of asthma, so not unexpectedly there are several 
definitions of severe asthma1,2,6,14–17 and these are described in table one.   In addition to severe 
asthma there are other terms such as “brittle” and “refractory” asthma which are not defined but 
may be used interchangeably with severe asthma.  The two themes common to all the definitions of 
severe asthma identified are poor control and high dose treatment (usually inhaled corticosteroid, 
ICS ≥400 micrograms budesonide or equivalent for children aged under 12 years and ≥1000 
micrograms in older children2).  Asthma attacks are included in some but not all definitions of severe 
asthma.  
Severe asthma can be broken down into two subcategories6.  A substantial proportion of individuals 
with severe asthma has symptoms which are due to modifiable factors which include poor or non-
adherence and/or poor inhaler technique, and these children and adolescents can be considered as 
having “difficult to treat asthma”.  The second subcat gory of severe asthma is termed “therapy 
resistant asthma” and describes children and adolescents whose symptoms are resistant (or in some 
cases partially resistant) to standard treatments such as inhaled and oral corticosteroids, long acting 
beta agonists and leukotriene modifiers.  There is a pressing need to categorise individuals correctly 
since management approaches to these two subcategories of severe asthma are divergent.  The 
management of difficult to treat asthma is rooted in education and psychology, whereas the 
management of therapy resistant asthma is “non-standard” pharmacological therapies.  To further 
complicate matters, many individuals with therapy resistant asthma also have characteristics of 
difficult to treat asthma. Ultimately the diagnosis of severe asthma, and its difficult to treat asthma 
and therapy resistant subcategories, is easiest made with the benefit of hindsight, but clinicians do 
not have this luxury during initial encounters with a patient whose asthma may be severe.
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Faced with a child or adolescent with a possible severe asthma diagnosis, clinicians need to consider 
possibilities which are more fully described elsewhere 1,6–8,18,19 and summarised here: 
1. Is this asthma? Conditions such as dysfunctional breathing, vocal cord dysfunction are 
increasingly recognised in children aged five years and above, and are reviewed elsewhere 
20,21.  Pertussis22 and habitual cough23 are commonly treated with escalating asthma 
medications in school aged children.  The “traditional” differential for asthma includes cystic 
fibrosis, primary ciliary dyskinesia, foreign body, immune deficiency, congenital airway 
pathologies such as tracheomalacia1, but these are predominantly considerations for the 
under five year olds.  Confirmation of the diagnosis includes typical symptoms, fixed airflow 
limitation and a response of symptoms and physiology to a defined period of supervised 
treatment1,2. 
2.  Is this difficult to treat asthma?  Inhaler technique is generally poor in children and 
adolescents24 and this can usually be easily identified and readily resolved.  Addressing poor 
or non-adherence is less straight forwards than addressing poor inhaler technique.  
Treatment non-adherence in asthma is reviewed elsewhere25.   Briefly, adherence to 
medication is a complex behaviour and non-adherence can be due to a number of factors 
including denial of the diagnosis, fear of harm from the medication, lack of understanding 
about the importance of taking the medication, not considering asthma a priority and having 
a secondary gain from the presence of symptoms, e.g. school avoidance.  Adherence can be 
categorised as intentional or unintentional.  Non-adherence can include situations where 
medication is never taken, medication is discontinued (by the patient) and medication is 
taken but not as frequently as prescribed.  Socioeconomic factors often contribute to poor 
adherence, and these include limited access to health care professionals and treatment.  
“Family factors” may also contribute to poor adherence, for example if the family has little 
or no organisation in the day-to-day running of the household then attention to taking 
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treatment is likely to be poor, and where there is scepticism or mistrust of healthcare 
professionals and treatment adherence can be expected to be poor.
3. Are there treatable co-morbidities?  Anxiety and allergic conditions such as rhinitis and 
eczema should be identified and managed since they can accompany and contribute 
towards poor quality of life for children and adolescents with severe asthma.  Other 
conditions such as obesity, obstructive sleep apnoea and gastro-oesophageal reflux disease 
(GORD) may accompany severe asthma but interventions aimed at reducing obesity or 
treating GORD have not been shown to improve asthma symptoms19.
4. Are there avoidable adverse environmental exposures contributing to symptoms? In the 
absence of a clear history of an exposure leading to symptoms, for example contact with a 
cat or eating a peanut, this can be difficult to ascertain.  A home visit may be revealing.  
Exposure to second hand smoke or visible mould in the bedroom may be contributory.  
5. Is this therapy resistant asthma? Consider corticosteroid resistance by non-response to a 
dose of triamcinolone or a burst of prednisone. 
6.  Might a bronchoscopy and biopsy help? This may be helpful in excluding a large airway 
pathology which is masquerading as asthma.  In some centres the role of airway biopsy in 
stratifying asthma treatment is being assessed19. 
Epidemiology of severe asthma
Studying the epidemiology of severe asthma is difficult due to its low prevalence, the use of different 
definitions and the presence of only a few whole population studies.  Key questions include what is 
the average age of a child with severe asthma? is there a difference in prevalence between males 
and females? And what is the prevalence of severe asthma? 
Severe asthma occurs across the paediatric age range, and in children aged less than five years is 
poorly understood.  Anecdotally, in the under five years age group severe exacerbations occur with 
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intercurrent upper respiratory tract infection against a back ground of relatively well-controlled 
symptoms, and this pattern is generally considered as distinct from severe asthma in older children.  
Cases series of treatment with intramuscular triamcinolone for severe asthma26–30 indicate that 
severe asthma is more common in the 12-15 year age group but there is no consistent male or 
female majority (table 2).  The 188 children with severe asthma in the Severe Asthma Research 
Program (SARP) III31 and the 99 children with severe asthma an initiative aimed at characterising 
severe asthma (U-BIOPRED)32 were typically 11-12 years old and 55-60% were male.  The complexity 
of the relationship between gender, age and asthma severity is demonstrated in an observational 
study of asthma which concluded that the proportion of asthmatic patients recruited who had 
severe asthma increased in boys as they became older (34% in the youngest and 59% in the oldest 
age group) but the proportion did not increase significantly as girls became older (33% and 52% 
respectively)33.  This study also found that among white children, 54% of 9-11 year olds with severe 
asthma were female increasing to 80% in the 15-17 year age group but this was not seen among 
black females33.  
Where it is described, severe asthma prevalence diminishes as more stringent definitions are 
applied, e.g asthma mortality versus prescribing of high dose inhaled corticosteroids (ICS) versus 
self-reported severity.  Routinely collected data indicate that the incidence of mortality from asthma 
in children is between 0 and 2 per million children per annum in European countries (figure one)34, 
but mortality may be as high as 7 per million per annum in some non-European countries35.  The 
international differences in mortality is illustrated when comparing data from the UK36 (3 per million 
per annum) and Finland37 (0.2 per million per annum), and this difference may reflect differences 
between healthcare systems.  Birth cohort studies from Northern Europe estimate the prevalence of 
severe asthma is between 2 and 5 per thousand children or 2-5% of all children with asthma38,39.  
Consistent with these findings, studies using primary care prescribing data in England40 and 
Scotland41 also found that approximately 5% of children with asthma were prescribed very high dose 
ICS.  A European study also found that 5% of parents of children with asthma scored their child’s 
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asthma as being severe3.  When using self-reported questionnaires, the prevalence of severe asthma 
symptoms (defined as ≥4 attacks of wheeze or ≥1 night per week sleep disturbance from wheeze or 
wheeze affecting speech in the past 12 months) in adolescents ranges between 38 and 51% with the 
higher proportions being seen in low and middle income countries35.
Systemic medications used for severe asthma
In the absence of high quality evidence, guidelines cannot say which medications should be 
considered beyond the “top step” of the stairway of escalating treatment. The mainstay of asthma 
treatment is inhaled corticosteroids and, when required, the addition of inhaled long acting beta 
agonists,  and leukotriene receptor antagonists and theophylline1,2. When these treatments are 
considered to be inadequate, treatment options mentioned in guidelines include long term oral 
corticosteroids, intramuscular omalizumab (an anti-IgE antibody) and anti- reflux treatments.  
Historically, “beyond the guidelines” treatments have followed an “ECG course” (figure one) where 
there is a spark of interest (P-wave) followed by a wave of enthusiasm shortly followed by a rapid loss 
of enthusiasm (QRS complex).  Finally, there is a small amount of use in some contexts and regions (T 
wave) before practice ceases completely.  Historically, experimental “beyond the guidelines” 
therapies which have been through the “ECG course” include oral macrolides, cyclosporin, cytotoxic 
drugs such as methotrexate and azathioprine, gold salts, intravenous infusions of Immunoglobulin, 
subcutaneous beta-agonist treatment and, in those sensitised to fungi, oral antifungal therapy with 
itraconazole or voriconazole8. This process of “trial and error” is now less commonplace and today’s 
novel therapies, for example biologics, emerge from a more robust scientific foundation.
Systemic corticosteroids
There is a high level of evidence that short bursts of oral corticosteroid (OCS) treatment (e.g. for 
three or five days) are effective in reducing the severity and duration of an asthma exacerbation in 
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children42.  This experience has been extrapolated to the different setting of chronic poorly 
controlled asthma symptoms, and some children and young peopleadolescents can receive 
maintenance daily or alternate daily OCS treatment for periods in excess of one month. There is 
absence of evidence for efficacy of “maintenance” OCS despite this treatment being in asthma 
guidelines1,2.  Maintenance OCS treatment should ideally be under the supervision of a respiratory 
expert who can minimise the risk for wrong diagnosis and likely distinguish difficult to treat asthma 
from therapy resistant asthma, but the use of maintenance OCS in severe childhood asthma remains 
an evidence-free area.  Most experienced paediatric pulmonologists can readily recall a (typically 
adolescent) patient who required maintenance OCS prescriptions for a period of months to gain 
symptom control and then were successfully weaned off their OCS.  
What is clear is that oral corticosteroid treatment is known to have adverse effects in children when 
used in short bursts (vomiting, behaviour change and sleep disturbance)43 and also for periods in 
excess of 14 days (weight gain, growth retardation, cushingoid features and susceptibility to 
infection)44.   The potential for harm from maintenance OCS to be greater than benefit is highlighted 
in BTS/SIGN guideline1 which states for adults (i.e. those aged >12 years): “add on low dose oral 
corticosteroids (7.5mg prednisolone daily) may be effective for some adults with severe asthma 
(Evidence D) but are associated with substantial side effects (Evidence B).”
Intramuscular Triamcinolone
Intramuscular treatment with triamcinolone may have a role in identifying steroid-responsive 
asthma, and may also provide treatment in severe asthma where adherence to inhaled and/or oral 
corticosteroids is in question (approximately 50% of adults with severe asthma are non-adherent 
with oral corticosteroid treatment45). Evidence supporting the use of this systemic treatment in 
children is limited to case series where different doses of triamcinolone are used26–30, see table two.  
In the largest case series, part of Tthe third phase of the US Severe Asthma Research Program (SARP 
III) Iincluded the largest case series where triamcinolone was used to treat asthma symptoms.  I, 188 
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children and 526 adults had extensive physiological assessments before and three weeks after a 
single dose of triamcinolone.  The aim of the study was to identify determinants of steroid 
responsiveness in 188 children and 526 adults who had extensive physiological assessments before 
and three weeks after a single dose of triamcinolone.  Triamcinolone treatment was associated with 
significant falls in exhaled nitric oxide and blood eosinophil count.  Among 111 children with severe 
asthma there was an improvement in symptoms and a non-significant trend for improved pre 
bronchodilator FEV1.  The apparent lack of response to triamcinolone in children with non-severe 
asthma is likely to be explained by a small sample size with few symptoms and good initial FEV1, and 
not by a lack of steroid-responsiveness.  A second in a case series of 79 children27, also sought to 
describe symptom and physiological outcomes four weeks after a single dose of intramuscular 
triamcinolone, which was given as part of a well-described pathway of care.  Children had improved 
symptom score (as evidenced by Asthma Control Test) and spirometry, and the differences were 
more clearly seen in children categorised as white compared to black.  Sputum eosinophilia, exhaled 
nitric oxide and intensive care unit admissions were all reduced after treatment but only among 
white children. 
A third prospectively-recruited case series28 identified children with an “unacceptably high level” of 
symptoms and admissions despite regular short bursts or continuous oral corticosteroid treatment 
and where adherence was considered adequate (including checking on the number of inhalers 
collected).  Individuals were given one treatment of triamcinolone or repeated treatments at one 
moth intervals. The number of exacerbations and hospital admissions during the treatment and post 
treatment phases fell relative to pre-treatment among those with repeated triamcinolone 
treatments.  Among those given a single treatment with triamcinolone, exacerbations but not 
hospital admissions were reduced.  In all participants, the number of day’s treatment with oral 
corticosteroid fell close to zero. Side effects were minimal and limited to the injection site. The 
authors conclude “Whether its [i.e. Triamcinolone] efficacy is due to improved compliance, or an 
improved anti-inflammatory profile compared with oral steroids, remains unclear”.   Two 
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retrospective case series published as separate abstracts29,30 and which are summarised in table 2 
report beneficial and adverse treatment outcomes in a total of 12 children.   
Collectively these data should be considered with caution since their “open label” design, absence of 
placebo and (in two cases29,30) their retrospective design mean that it is not reasonable to infer 
beyond doubt that any benefits arose from triamcinolone treatment.  The worrying side effects 
reported in one series29 should be considered, albeit other case series did not mention side 
effects27,30 and the fourth study mentioned only minor local effects28.  As with most asthma 
treatments, response to triamcinolone is not homogeneous and results from one study indicate that 
a response may be more clearly seen in white children compared to black27.  When adherence to 
maintenance oral corticosteroid t eatment is uncertain and the child or young person is experiencing 
severe or life-threatening asthma exacerbations, then it would be reasonable to start a short trial of 
triamcinolone treatments to demonstrate whether symptoms are steroid responsive.  If there is no 
response to at least two months treatment and/or side effects develop then treatment might be 
discontinued.  If there is a response (in asthma control and number of exacerbations) then strategies 
to improve inhaled or oral corticosteroid adherence should be explored.
Omalizumab
The anti-IgE antibody omalizumab has been used for the treatment of severe asthma in children 
aged 6-11 years since 2009, and in older children and adults since 2003.  At least ten randomised 
controlled trials in children have explored the efficacy of omalizumab in a range of settings including 
“persistent asthma”, “severe asthma” and “moderate-to-severe atopic asthma” and the consensus is 
that treatment is safe and effective in reducing asthma exacerbations (especially in the September 
peak in asthma exacerbations), reducing ICS dose and reducing symptoms46.  When first introduced, 
there were concerns about anaphylaxis and increased risk for malignancies (mostly extrapolated 
from anxieties about infliximab, an antibody specific for tumour necrosis factor), but a recent review 
noted that risk of anaphylaxis was approximately 0.2% per treatment and there was no excess of 
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malignancies46.  Omalizumab is not suitable for all patients, the largest trial47 included in a recent 
review46 found that the majority (59%) of potential participants were ineligible.  The monthly 
subcutaneous injection is uncomfortable, requires administration in a healthcare setting with 
nursing observations and is expensive.  What remains to be clarified is whether it is superior to high 
dose ICS, and how and when treatment should be discontinued. 
Mepolizumab
The anti-interleukin-5 molecule mepolizumab was licenced in Europe for use in children aged 6-11 in 
August 2018 and has been licenced for use in older children in the US and Europe since 2015.  
Experience with this “mab” in adults was initially mixed, with some studies finding improved asthma 
outcomes but most studies reported severe headaches48; a definitive trial found that mepolizumab 
was effective in reducing asthma exacerbations and a licence was granted in 201548.
The license in Europe for children is based only on safety data from a single study of 36 6-11 year 
olds49. Inclusion criteria included: having an asthma diagnosis for more than 12 months; at least two 
exacerbations in the year prior to recruitment; receiving ≥400 micrograms budesonide (or 
equivalent); receiving an additional controller medication for more than three months; an FEV1/FVC 
ratio of <0.8 and blood eosinophilia (>0.15x109/l on recruitment or >0.3 x109/l in the year prior to 
recruitment).  In keeping with the adult experience, headaches were a common side effect.  Clinical 
improvements were not sought in this phase II trial so the efficacy of this treatment remains 
uncertain in children.  Given the challenge in recruiting children fulfilling these inclusion criteria it is 
likely that a randomised clinical trial will not be carried out.  
Data from studies in adults (but including participants as young as 12 years) have demonstrated the 
efficacy of mepolizumab for reducing risk of asthma exacerbations.  The DREAM study enrolled 621 
participants (159 received a placebo), who had at least two asthma attacks in the previous year, 
“airway variability” (i.e. either peak flow variability, bronchial hyperresponsiveness or 
bronchodilator response) and eosinophilia (i.e. elevated exhaled nitric oxide or blood eosinophilia).  
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Treatment with one of three doses of mepolizumab was associated with between a 39-52% 
reduction in the rate of exacerbations, but there was no improvement in asthma control between 
the placebo and treatment groups50.  The MENSA study recruited 576 participants aged 12-82 years 
of whom 191 received placebo treatment and who had very similar characteristics to the DREAM 
study (namely two recent asthma attacks, airway variability and eosinophilia).  There was 
approximately a 50% reduction in asthma exacerbations for those treated with mepolizumab 
compared to placebo and also a small improvement in asthma symptoms (but which was not greater 
than the minimal clinically important change)51. 
For patients aged twelve years and older, there are two other anti IL5 pathway specific therapies 
licensed (benralizumab and reslizumab).  A recent review of the literature suggests that whilst all 
three anti IL-5 pathway specific therapies are more effective than placebo in reducing exacerbations 
and improving symptom control, mepolizumab has the greater benefit52. 
Dupilumab 
Dupilumab is an IL-4 and IL-13 antibody which is licensed in the US and European Union for the 
management of severe asthma in individuals who are aged 12 years and older.  The LIBERTY 
ASTHMA QUEST study 53 recruited 1902 participants aged at least 12 years who were randomised to 
either placebo or one of two subcutaneous doses of dupilumab given at two weekly intervals over a 
12 month period.  Inclusion criteria included: prescribed medium-high dose ICS treatment; 
prescribed an additional controller; FEV1 <80% (or ≤90% for 12-17 year olds); bronchodilator 
reversibility (>12% or 200mls); poor symptom control (Asthma Control Questionnaire score ≥1.5); 
and an asthma attack requiring systemic glucocorticosteroid treatment in the last year.  The primary 
outcome was exacerbation rate and, as seenm for other “-mabs” the rate of exacerbations was 
reduced by approximately half (47.7%) in those receiving active treatment compared to placebo.  
The dupilumab group had improved symptom scores after two week’s treatment and thereafter 
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throughout the study, also they had a mean increase of 140mls in FEV1 compared to the placebo 
group.  Eosinophilia (i.e. >300 eosinophils per cubic millimetre) occurred in 4% of participants who 
received dupliumab and 0.64% who received placebo, the clinical significance of this is uncertain.
Gastro-oesophageal reflux treatment
Gastro-oesophageal reflux disease (GORD) is commonly present in adults and children with asthma.  
In the adult literature there was evidence of benefit (in terms of improved lung function) when 
patients with night time respiratory symptoms and GORD were treated with esomeprazole54 but this 
same medication is not associated with improved lung function or symptoms in the absence of 
GORD symptoms54,55.   but, Ddespite the relationship not being thought to be causal1, a trial of GORD 
treatment is sometimes used in children with severe asthma.  The evidence base for this practice is 
very narrow.  One randomised controlled trial has explored the benefit of a proton pump inhibitor 
(Lansoprazsole) in poorly controlled (not severe) asthma in 306 children aged 6-17 years56. Eligibility 
criteria included receiving a dose of ICS >175 micrograms/day fluticasone (or equivalent), evidence 
of airway reversibility or hyperresponsiveness, need for short acting beta agonist treatment more 
than two days a week and two asthma exacerbations in the past year.  Children and young 
peopleadolescents with overt GORD symptoms were excluded. Just over 40% of participants tested 
had evidence of GORD.  After 24 weeks there were no differences in asthma outcomes between 
those who received lansoprasole compared to placebo.  Unexpectedly the active medication was 
associated with increased risk for respiratory infection.  
Conclusions
Severe asthma in children will continue to be a clinical challenge and brings a risk of morbidity and 
mortality due to the disease itself and also potentially from the treatment offered.  This review has 
highlighted ongoing areas of uncertainty in the definition, the epidemiology and the medical 
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treatment of severe asthma (table three).  The future is likely to continue to bring more treatment 
options for severe asthma which may offer benefit but also may prove to be a “flat line” after the 
ECG course.  For example the roles of long acting muscarinic agonists, macrolide antibiotics and 
bronchial thermoplasty in children are unknown at present, but will likely be explored in future.   
There is a sound evidence base that electronic logging of inhaled corticosteroid treatment leads to 
improved asthma outcomes, and such meters may become more commonly used in clinical 
practice57,58.  Directly observed inhaler treatment using video conference technology may also be 
useful in some situations59.  Among other non-medicinal interventions there are new “uncertainties” 
such as temperature-controlled laminar airflow60 and old “uncertainties” such as dust mite 
impermeable bedding61.  Severe asthma will always test clinical teams and sometimes call for 
difficult decisions to be made.  Key to management are involving the asthma team, speaking to other 
professionals involved (e.g. teachers) and personalising care.
Research needs
These are some areas where further research might advance the care for children and young 
peopleadolescents with severe asthma.
 What is the prevalence and incidence of severe asthma in children (using different 
definitions)? 
 What objective tests are most effective in distinguishing between difficult to treat and 
therapy resistant asthma (e.g. spirometry, plasma prednisolone concentration, inhaler 
logging devices, directly observed therapy)?
 How and when should treatment with maintenance oral corticosteroids and intramuscular 
triamcinolone or biologics begin and when might they and omalizumab be stopped?
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FIGURE LEGENDS
Figure one. Schematic “ECG” summarising the ups and downs of enthusiasm for many novel 
treatments which have been used for severe asthma in the past, but which are no longer used8.  In 
this metaphor, treatment is first proposed as being potentially of use (P wave), then followed by a 
surge of enthusiasm (upwards limb of the QRS complex) followed by reality (downwards limb of the 
QRS complex), then a short burst of use by a few enthusiast (T wave) after which the medication is 
never used.
Figure two. The incidence of asthma morbidity in 21 countries in the World health Organisation 
European Region averaged between 2006 and 2015.  Only countries where data were available in 
each year and where at least one year had an incidence which was not zero.  Data were available 
between 2006-2015 and the incidence was zero throughout from the following countries: Cyprus, 
Estonia, Israel, Lithuania and Malta.
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